You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》野村:中資CRO股已呈超賣 相信美行政命令非特別針對華生物技術 料影響有限
藥明生物(02269.HK)今早股價反彈,盤中曾高見55.3元一度彈高8.9%,最新報54.5元回升7.4%,藥明康德(02359.HK)股價揚6.8%,康龍化成(03759.HK)漲4.1%。 野村發表報告表示,在中國從事受託研究機構(CRO)行業的股份已呈超賣,並預計該行業將獲得一些進展。該行指,從美國總統拜登的相關行政命令和白宮於昨日(14日)舉行的生物技術和生物製造峰會中獲得的一些結論,認為美方相關行政命令對中國生物技術和中國CRO的影響有限。 該行又指,美方行政命令以及要實施的詳細舉措涵蓋了廣泛的領域,包括生物供應鏈、生物製造、生物產品,從原料藥、燃料、聚合物、肥料廢物和氣候變化。該行認為相關命令不是特別針對中國生物技術或CRO。一些與會嘉賓以中立的語氣討論中國相關事宜。 該行指,美國政府將投資約20億美元促進生物技術和生物製造,旨在降低價格、創造良好的就業機會、加強供應鏈等。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account